Clinical trial of transcathether arterial chemoembolization combined with non-cytotoxic drugs in hepatocellular carcinoma

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-11000173

Enrollment

Unknown

Registered

2011-01-24

Start date

2007-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma (HCC)

Interventions

Control group:Not receive any treatment for HCC

TACE+COX+LAN group:Receive TACE, celecoxib and lanreotide

TACE+COX group:Receive TACE and celecoxib

TACE group:Receive TACE therapy

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Child-Pugh grade A-B; (2) HCC confirmed and have not been or is not being treated; (3) not suitable for curative treatment, CLIP score 2-5.

Exclusion criteria

Exclusion criteria: 1. Advanced liver disease (Child-Pugh class C); 2. Active gastrointestinal bleeding, encephalopathy, refractory ascites, extrahepatic spread; portosystemic shunt, hepatofugal blood flow; 3. Impaired clotting tests (platelet count < 50*10^9/L or prothrombin activity < 50%); 4. Karnofsky score < 70; 5. Pregnant or breeding women; 6. Hyperallergic to drugs involved in this study or sulfanilamide; 7. Other severe systemic diseases.

Design outcomes

Primary

Measure	Time frame
Survival time and survival rate;	—

Secondary

Measure	Time frame
quality of life;Response;	—

Contacts

Public ContactChengwei Tang

shcqcdmed@163.com+86 18980601275

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026